

Selpercatinib

for advanced or metastatic thyroid cancer with *RET* alterations

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Selpercatinib 40 mg and 80 mg capsules and tablets as monotherapy for:
 - patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a *rearranged during transfection (RET)* mutation who require systemic therapy; and
 - patients 12 years of age and older with advanced or metastatic thyroid cancer with a *RET* gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

in view of clinical need, and acceptable clinical effectiveness, safety, and pricing proposal by the company.

Funding status

Selpercatinib 40 mg and 80 mg capsules and tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 September 2026.

Clinical indications, subsidy class and MediShield Life claims eligibility for selpercatinib are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

| Drug preparation | Approved clinical indication | Subsidy class (implementation date) | Eligible for MediShield Life claims (implementation date) |
|--|---|-------------------------------------|---|
| Selpercatinib 40 mg, 80 mg capsules and tablets | Monotherapy for the treatment of patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a <i>RET</i> mutation who require systemic therapy. | MAF (1 Sep 2026) | Yes ¹ (1 Sep 2026) |
| | Monotherapy for the treatment of patients 12 years of age and older with advanced or metastatic thyroid cancer with a <i>RET</i> gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). | MAF (1 Sep 2026) | Yes ¹ (1 Sep 2026) |

Abbreviation: MAF, Medication Assistance Fund; *RET*, *rearranged during transfection*.

¹ Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
 Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.